Logo image of MOR

MorphoSys AG (MOR) Stock Overview

USA - NASDAQ:MOR - US6177602025 - ADR

18.96 USD
+0.45 (+2.43%)
Last: 8/2/2024, 8:20:34 PM
18.96 USD
0 (0%)
After Hours: 8/2/2024, 8:20:34 PM

MOR Key Statistics, Chart & Performance

Key Statistics
Market Cap2.86B
Revenue(TTM)203.50M
Net Income(TTM)-460265360
Shares150.65M
Float18.44M
52 Week High19.5
52 Week Low4.18
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-3.38
PEN/A
Fwd PEN/A
Earnings (Next)08-29 2024-08-29/amc
IPO1999-03-09
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


MOR short term performance overview.The bars show the price performance of MOR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60

MOR long term performance overview.The bars show the price performance of MOR in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300

The current stock price of MOR is 18.96 USD. In the past month the price increased by 1.94%. In the past year, price increased by 144.65%.

MorphoSys AG / MOR Daily stock chart

MOR Latest News, Press Relases and Analysis

MOR Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.3 398.39B
AMGN AMGEN INC 13.37 157.02B
GILD GILEAD SCIENCES INC 15.2 146.02B
VRTX VERTEX PHARMACEUTICALS INC 24.74 107.44B
REGN REGENERON PHARMACEUTICALS 14.51 69.21B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 62.38B
ARGX ARGENX SE - ADR 90.34 51.23B
INSM INSMED INC N/A 35.04B
ONC BEONE MEDICINES LTD-ADR 5.06 34.49B
NTRA NATERA INC N/A 26.39B
BNTX BIONTECH SE-ADR N/A 25.29B
BIIB BIOGEN INC 9.29 21.81B

About MOR

Company Profile

MOR logo image MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. The company is headquartered in Planegg, Bayern and currently employs 464 full-time employees. The firm discovers, develops, and delivers cancer medicines to patients. The company markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.

Company Info

MorphoSys AG

Semmelweisstr. 7

Planegg BAYERN 82152 DE

CEO: Jean-Paul Kress

Employees: 464

MOR Company Website

Phone: 4989899270

MorphoSys AG / MOR FAQ

What does MOR do?

MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. The company is headquartered in Planegg, Bayern and currently employs 464 full-time employees. The firm discovers, develops, and delivers cancer medicines to patients. The company markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.


Can you provide the latest stock price for MorphoSys AG?

The current stock price of MOR is 18.96 USD. The price increased by 2.43% in the last trading session.


Does MOR stock pay dividends?

MOR does not pay a dividend.


How is the ChartMill rating for MorphoSys AG?

MOR has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Should I buy MOR stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MOR.


Can you provide the market cap for MorphoSys AG?

MorphoSys AG (MOR) has a market capitalization of 2.86B USD. This makes MOR a Mid Cap stock.


When does MorphoSys AG (MOR) report earnings?

MorphoSys AG (MOR) will report earnings on 2024-08-29, after the market close.


MOR Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to MOR. When comparing the yearly performance of all stocks, MOR is one of the better performing stocks in the market, outperforming 98.16% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

MOR Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to MOR. Both the profitability and financial health of MOR have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MOR Financial Highlights

Over the last trailing twelve months MOR reported a non-GAAP Earnings per Share(EPS) of -3.38. The EPS decreased by -160.42% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -25.13%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-518.18%
Sales Q2Q%-55.81%
EPS 1Y (TTM)-160.42%
Revenue 1Y (TTM)-31.97%

MOR Forecast & Estimates

12 analysts have analysed MOR and the average price target is 5.06 USD. This implies a price decrease of -73.33% is expected in the next year compared to the current price of 18.96.

For the next year, analysts expect an EPS growth of 20.86% and a revenue growth -3.33% for MOR


Analysts
Analysts70
Price Target5.06 (-73.31%)
EPS Next Y20.86%
Revenue Next Year-3.33%

MOR Ownership

Ownership
Inst Owners1.03%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A